# Gallocyanine chloride

**Cat. No.:** HY-D0961

**CAS No.:** 1562-85-2

**Molecular Formula:** $C_{15}H_{13}ClN_2O_5$

**Molecular Weight:** 336.73

**Target:** Wnt

**Pathway:** Stem Cell/Wnt

**Storage:** 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : ≥ 11.11 mg/mL (32.99 mM)
* "≥" means soluble, but saturation unknown.

**Preparing Stock Solutions**

| Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.9697 mL | 14.8487 mL | 29.6974 mL |
| 5 mM | 0.5939 mL | 2.9697 mL | 5.9395 mL |
| 10 mM | 0.2970 mL | 1.4849 mL | 2.9697 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 0.53 mg/mL (1.57 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 0.53 mg/mL (1.57 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

Gallocyanine chloride, a synthetic blue dyestuff, blocks DKK1 inhibitory activity by disrupting DKK1/LRP6 interaction. Its association with LRP6 is weak ($IC_{50}$ of about 3 μM in the inhibition of DKK1 binding). Gallocyanine dye acts as a potential agent for the research of Alzheimer's disease and related neurodegenerative tauopathies[1].

## REFERENCES

[1]. Spyros Mpousis, et al. Synthesis and evaluation of gallocyanine dyes as potential agents for the treatment of Alzheimer's disease and related neurodegenerative tauopathies. Eur J Med Chem. 2016 Jan 27;108:28-38.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA